Refractory chronic cough acquires a first targeted mechanism class
P2X3 antagonist class entry plus follow-on novel mechanism programs are establishing chronic cough as a real prescribing category.
Refractory chronic cough has been a category with no specifically-targeted therapy. P2X3 antagonist gefapixant entry, follow-on P2X3 programs, and novel non-P2X3 mechanism programs (including TRP channel modulators and others) are establishing a real prescribing category. The diagnostic-pathway question is significant; refractory chronic cough is often misattributed to other conditions for years before correct identification.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.